ArticlePain and therapy2026
Quadratus Lumborum Block versus Thoracic Paravertebral Block for Postoperative Recovery Quality after Percutaneous Nephrolithotomy: A Randomized Noninferiority Trial.
Article in Pain and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
introductionWe aimed to determine whether anterior quadratus lumborum block (QLB) at the lateral supra-arcuate ligament is noninferior to thoracic paravertebral block (TPVB) for postoperative recovery quality after percutaneous nephrolithotomy (PCNL).
methodsA total of 72 adults (American Society of Anesthesiologists physical status I-II) undergoing elective unilateral PCNL were randomized to QLB (n = 36) or TPVB (n = 36). Before general anesthesia, patients received ultrasound-guided anterior QLB (0.5% ropivacaine, 30 mL) or TPVB (0.5% ropivacaine, 20 mL), with standardized multimodal analgesia including patient-controlled intravenous morphine. The primary outcome was the Quality of Recovery-15 (QoR-15) score at 24 h; noninferiority required the lower bound of the 95% confidence interval (CI) for the difference (QLB minus TPVB) to exceed the prespecified margin of -6 points in both the modified intention-to-treat and per-protocol populations. Secondary outcomes were pain intensity, morphine consumption, patient satisfaction, and adverse events.
resultsMedian QoR-15 scores at 24 h were 124 (interquartile range [IQR], 118-128) for QLB and 122 (IQR, 117-125) for TPVB (median difference, 2; 95% CI, -1 to 5; p < 0.001 for noninferiority), robust at stricter margins and confirmed per protocol. In secondary and exploratory analyses, QLB prolonged time to first analgesia (from postanesthesia care unit [PACU] admission; restricted mean survival time difference, 7.9 h; 95% CI, 5.9 to 9.8; time-averaged hazard ratio, 0.18; 95% CI, 0.10 to 0.31; p < 0.001), reduced 24-h morphine consumption (-4 mg; 95% CI, -6 to 0; p = 0.035), and lowered pain area under the curve at rest (-10 cm·h; 95% CI, -15 to -4) and on movement (-15 cm·h; 95% CI, -22 to -8; both p < 0.001). Hypotension occurred in 4 of 35 patients (11%) with QLB versus 13 of 36 (36%) with TPVB (relative risk, 0.32; 95% CI, 0.11 to 0.88; p = 0.015).
conclusionsAnterior QLB was noninferior to TPVB for postoperative recovery quality after PCNL. Associated reductions in pain and opioid use, and a lower observed incidence of hypotension, seen in secondary and exploratory analyses, are hypothesis-generating and warrant confirmation. Graphical abstract available for this article.
trial registrationChinese Clinical Trial Registry, ChiCTR2100044431.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.